Shopping Cart
Remove All
Your shopping cart is currently empty
UTL-5g (3-Isoxazolecarboxamide, N-(2,4-dichlorophenyl)-5-methyl-) is a novel potential chemoprotective agent, TNF-α inhibitor that reduces cisplatin-induced side effects including nephrotoxicity, hepatotoxicity and hematotoxicity. It lowers elevated levels of AST, ALT, creatinine, BUN, and TNF-α, increases the reduced platelet count in mice, and acts as a novel chemo- and radioprotective agent.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $43 | In Stock | In Stock | |
| 5 mg | $107 | In Stock | In Stock | |
| 10 mg | $167 | In Stock | In Stock | |
| 25 mg | $338 | In Stock | In Stock | |
| 50 mg | $476 | In Stock | In Stock | |
| 100 mg | $678 | In Stock | In Stock | |
| 200 mg | $913 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $117 | In Stock | In Stock |
| Description | UTL-5g (3-Isoxazolecarboxamide, N-(2,4-dichlorophenyl)-5-methyl-) is a novel potential chemoprotective agent, TNF-α inhibitor that reduces cisplatin-induced side effects including nephrotoxicity, hepatotoxicity and hematotoxicity. It lowers elevated levels of AST, ALT, creatinine, BUN, and TNF-α, increases the reduced platelet count in mice, and acts as a novel chemo- and radioprotective agent. |
| In vivo | UTL-5g (GBL-5g) reduces elevated TGF-β and TNF-α levels resulting from lung irradiation[1]. |
| Synonyms | GBL-5g, 3-Isoxazolecarboxamide, N-(2,4-dichlorophenyl)-5-methyl- |
| Molecular Weight | 271.1 |
| Formula | C11H8Cl2N2O2 |
| Cas No. | 646530-37-2 |
| Smiles | Cc1cc(no1)C(=O)Nc1ccc(Cl)cc1Cl |
| Relative Density. | 1.469 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 27.5 mg/mL (101.44 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Corn Oil: 2 mg/mL (7.38 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.